ONCOTECH LTD
OncoTech Ltd is a London-based private company founded in 2019 that develops AI-based cancer screening technologies and oncology therapeutics. Public information on its products, operations, and commercialization is severely limited.
- Company typePrivate
- Founded2019
- HeadquartersLondon, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingSoftware
What ONCOTECH LTD does
OncoTech Ltd is a privately held UK-based company, founded in 2019 and headquartered in London. According to its firmographic profile, the company develops AI-based cancer screening technologies and oncology therapeutics, positioning it at the intersection of applied artificial intelligence and oncology drug development. The company maintains a web presence at oncotech.global, which targets a global audience via its top-level domain choice.
Beyond the high-level self-description, no verifiable information was available regarding OncoTech's specific product portfolio, underlying technology architecture, intellectual property holdings, funding history, management team, partnership network, customer base, revenue model, pricing, certifications, regulatory milestones, headcount, or go-to-market strategy. The company's own website (oncotech.global) was non-functional at the time of data collection, displaying only a loader/verification screen, and third-party data sources did not return substantive corporate, financial, or operational information. This combination of signals — a non-functional primary web presence combined with the absence of any corroborating data on funding, personnel, customers, or pipeline assets — implies either a very early/pre-commercial stage of development, limited public disclosure, or potential dormancy, and any investment-grade assessment will require primary-source verification of capitalization, pipeline status, and operational activity before substantive judgments can be made.
ONCOTECH LTD firmographics
Firmographics- Name
- ONCOTECH LTD
- Website
- https://oncotech.global
- Company type
- Private
- Founded year
- 2019
- Short description
- OncoTech Ltd is a London-based private company founded in 2019 that develops AI-based cancer screening technologies and oncology therapeutics. Public information on its products, operations, and commercialization is severely limited.
- Ownership category
- akta.pro rank
ONCOTECH LTD industry classification
Industry- Product category
- Oncology AI Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Medical Oncology (HLAKAFAB)
Keywords
Where ONCOTECH LTD is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
ONCOTECH LTD business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel
ONCOTECH LTD product offering
Product offeringCore offering
OncoTech develops AI-based cancer screening technologies and oncology therapeutics. The company combines artificial intelligence with oncology to enable early cancer detection and advance therapeutic development for cancer patients.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-based cancer screening technology Artificial intelligence-based cancer screening technology for early cancer detection, targeting healthcare providers and oncology stakeholders.
- Oncology therapeutics Oncology therapeutics developed by OncoTech for cancer treatment, targeting oncology patients and healthcare providers.
Companies that use ONCOTECH LTD
Customer profileIdeal customer profiles1 record
ONCOTECH LTD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ONCOTECH LTD partnerships and signals
Strategic signalExpansion highlights1 record
ONCOTECH LTD competitors and assessment
Company assessmentDirect peers
- Owkin: AI biotech combining federated learning, diagnostics, and therapeutic development in oncology — closely aligned with OncoTech's positioning in Europe and its dual focus.
- PathAI: AI pathology platform focused on cancer diagnostics and biomarker discovery, partnering with pharma for therapeutic development — closely aligned with OncoTech's dual screening + therapeutics scope.
- Paige.AI: AI company applying deep learning to pathology and cancer diagnostics, with FDA-authorized products — a direct comparable for AI-based cancer screening technology.
- Tempus AI: AI-driven precision medicine company combining multimodal data, diagnostics, and therapeutic insights in oncology — directly comparable to OncoTech's AI cancer screening and oncology therapeutics focus.
- Exscientia: AI-driven drug discovery company with oncology pipeline, merged with Recursion — comparable for combining AI technology platform with proprietary therapeutic programs.
- Recursion Pharmaceuticals: AI-native biopharma applying machine learning to drug discovery across oncology and other areas; comparable for its combination of AI technology platform with therapeutic development.
Broad incumbents
- Foundation Medicine (Roche): Established leader in oncology molecular profiling and companion diagnostics, owned by Roche; represents the scaled incumbent in cancer screening/diagnostics that AI-driven players compete against.
- Exact Sciences: Public diagnostics company with cancer screening products (Cologuard, Oncotype); represents an established incumbent in cancer screening that any AI-driven screening entrant must differentiate against.
- GRAIL: Well-capitalized cancer screening company developing multi-cancer early detection tests, backed by Illumina; represents a scaled competitor in the cancer screening category.
Emerging players
- Freenome: Multiomics platform for early cancer detection using AI on blood-based biomarkers; comparable as an AI-enabled cancer screening competitor with similar technology approach.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights3 records
Customer concentration
ONCOTECH LTD social profiles
Digital presenceONCOTECH LTD financial estimates
Financial estimateRevenue estimate
Valuation estimate
ONCOTECH LTD leadership team
Management profileNumber of profiles
ONCOTECH LTD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ONCOTECH LTD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ONCOTECH LTD
What does ONCOTECH LTD do?
OncoTech develops AI-based cancer screening technologies and oncology therapeutics. The company combines artificial intelligence with oncology to enable early cancer detection and advance therapeutic development for cancer patients.
When was ONCOTECH LTD founded?
ONCOTECH LTD was founded in 2019.
Where is ONCOTECH LTD based?
ONCOTECH LTD is headquartered in London, United Kingdom, in the Europe region.
Who are ONCOTECH LTD's main competitors?
Direct peers on record are Owkin, PathAI, Paige.AI, Tempus AI, Exscientia and Recursion Pharmaceuticals. Broad incumbents are Foundation Medicine (Roche), Exact Sciences and GRAIL. Freenome is listed as an emerging player.
Does ONCOTECH LTD have an API?
No public API is recorded for ONCOTECH LTD.
What industry is ONCOTECH LTD in?
ONCOTECH LTD's product category is Oncology AI Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2835.